In lung adenocarcinomas patients, EGFR mediates the activation of RET with neuroendocrine differentiation characterized by ASCL1 expression, implicating that EGFR is a key regulator of RET (Tang et al., 2015). Here, ASCL1 is linked to lung adenocarcinoma.